The key stage of pre-clinical trials for the first domestic solution to preserve donor organs has commenced at the Turner National Medical Research Center for Pediatric Orthopedics and Trauma. The solution was developed by OOO Polisan.
Previously, only imported solutions were used in clinical practice for organ preservation. The drug created by Polisan’s scientists is designed to replace foreign analogs and ensure the independence of Russian transplantology from external supplies, the project authors reported.
The trials are taking place at the Gaivoronsky Laboratory of Experimental Traumatology and Orthopedics. Surgeons are performing highly complex kidney transplant operations on laboratory rats: the organ is extracted, placed in the test solution, and then transplanted to a recipient. The initial results have demonstrated the solution’s high safety and efficacy: the transplanted kidneys are functioning well, and the animals are recovering quickly, the scientists reported.
“Developing our own preservation solution is a challenging scientific task, as our goal is not only to create the drug but also to ensure its adoption in clinical practice to save lives as soon as possible. For us, this project is part of a long-term strategy for developing innovative solutions in the field of biomedical technologies and supporting the country’s scientific sovereignty,” said Andrey Petrov, Deputy Director for Science at Polisan.
The trials will continue until the end of 2025. Based on the results, a decision will be made on transitioning to subsequent stages, including drug registration and preparation for human trials.
The project is being implemented with the support of the St. Luke Clinical Hospital, the Shumakov National Medical Research Center for Transplantology and Artificial Organs, and the Smorodintsev Research Institute of Influenza.
